Jaime Rosenberg

Data from a post hoc analysis is adding to positive literature on vagus nerve stimulation, concluding that the treatment quickly and consistently reduced pain intensity while decreasing rescue medication use among patients with episodic migraine.

Citing the low level of reporting and subsequent drop of 8462 individuals from coverage, the Medicaid and CHIP Payment and Access Commission (MACPAC) said that the current process is likely not structured in a way that provides enrollees an opportunity to succeed under the requirements and, as a result, is calling for a pause in disenrollments in order to make proper adjustments to the program.

Elevated blood pressure and stage 1 and 2 hypertension before age 40 puts young adults at higher risk for cardiovascular disease (CVD) events later in life compared to those with normal blood pressure, according to a new study published in JAMA.

Hispanics living with HIV are at an increased risk of developing cancers caused by the human papillomavirus (HPV) compared to the general Hispanic population, and among people living with HIV, Hispanics are more likely to be diagnosed with cervical and penile cancer.

Adjusted incidence rate ratios showed that febrile neutropenia following chemotherapy carried an approximately 2-fold risk of long-term infection.

November marks Lung Cancer Awareness Month, which seeks to put a spotlight on the leading cause of cancer death. Here are 5 things to know about the disease.

Recognizing a need for an outcome indicator for those newly diagnosed with HIV, researchers have proposed including the percentage of newly diagnosed persons achieving viral suppression within 3 months of diagnosis.

Following indications of an association between migraine and attention deficit and hyperactivity disorder (ADHD) in children and adolescents, a new study has demonstrated a significant comorbidity of the 2 conditions in adults.

Among women with HIV, there is an increased risk of neutropenia during chemoradiotherapy treatment for cervical cancer and they are less likely to complete chemotherapy with cisplatin.

A study of more than 120,000 patients found that increasing physical performance is inversely associated with long-term mortality with no observed upper limit of benefit.

Building on positive 48-week data, Janssen released 96-week data demonstrating high rates of virogolic suppression and tolerability among antiretroviral therapy-naïve adults with HIV-1.

Following more than 1000 people living with HIV who were recently incarcerated, researchers observed that retention in care diminished significantly over time, but it was associated with HIV care during incarceration, health insurance, case management services, and early linkage to care post release.

According to a study presented at the ESMO 2018 Congress in Munich, Germany, treatment with PD-1 or PD-L1 inhibitors is a feasible option for patients who have cancer and are living with HIV.

In reponse to rising healthcare prices and emergency department (ED) visits, insurers have implemented policies that apply financial disincentives for ED visits that could presumably be cared for in alternative settings. However, 87.9% of commercially insured ED visits present with the same primary symptoms as visits that result in nonemergent diagnoses.

A new study has indicated that long-term treatment with onabotulinumtoxin A is effective, safe, and well-tolerated in the patient population.

Certain dermatologic/mucosal conditions, use of corticosteroids, and intravenous antibiotics prior to chemotherapy may increase the risk of febrile neutropenia.

A population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men resulted in a 25% reduction in HIV diagnoses in just 1 year.

A study has found no evidence that bleomycin plus granulocyte-stimulating factor (G-CSF) increases the risk for bleomycin-induced pulmonary toxicity in patients with Hodgkin lymphoma.

Starting April 1, 2019, Express Scripts will offer its SafeGuardRx Migraine Care Value program, which will help patients achieve better outcomes with preventive therapies and offer a value-based design for plan sponsors.

The novel vaccine—eOD-GT8 60mer—stimulates the immune system to initiate a key first step in the generation of potent proteins, known as broadly neutralizing antibodies.

Patient-reported outcomes (PROs) have the potential to enhance drug development, regulatory decisions, and shared decision making, and the benefits of using PROs are broadly agreed upon, but there are a variety of challenges facing stakeholders.

Today, HHS announced that approximately $2.34 billion in Ryan White HIV/AIDS Program grants were awarded to cities, counties, states, and local community-based organizations during fiscal year 2018.

Although researchers observed improvements when incorporating several new comorbidities into chemotherapy-induced febrile neutropenia risk factors, the improvements were small and might not be clinically relevant.

Researchers compiled data from 2 studies demonstrating the safety and efficacy of erenumab at 4 weeks and found that the treatment resulted in a reduction of weekly migraine days as early as week 1.

According to the 2018 benchmark Kaiser Family Foundation Employer Health Benefits Survey, annual premiums for family and single coverage have increased in 2018 and the burden of deductibles continues to grow on employees. However, as premiums rise, so does employer investment in health and wellness programs for their employees.

Treatment with Symtuza (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) results in and maintains high virologic suppression rates, according to study findings presented at the 2018 Infectious Disease Week conference held in San Francisco, California.

During a session at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlined the biggest news and updates in the treatment of neuroendocrine tumors (NETs).

During a session at the North American Neuroendocrine Tumor Society (NANETS) annual meeting, held October 4-6 in Seattle, Washington, Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, gave an overview of updates made to lung neuroendocrine tumor guidelines.